Edgar Filing: Ardea Biosciences, Inc./DE - Form SC 13D/A

Ardea Biosciences, Inc./DE Form SC 13D/A December 19, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D Under the Securities Exchange Act of 1934

(Amendment No. 6)

ARDEA BIOSCIENCES, INC. (Name of Issuer)

Common Stock, par value \$0.001 per share (Title of Class of Securities)

03969P107 (CUSIP Number)

Leo Kirby 667 Madison Avenue, 17th Floor New York, NY 10021 (212) 339-5633

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 19, 2008 (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.	03969P107		Page	2 of 6	Pages		
NA 1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS						
₂ CH	an C. Baker ECK THE APPROPRIATE OUP (See Instructions)	MEMBER C	OF A	(a) o (b) o			
	SEC USE ONLY				(0) 0		
4	SOURCE OF FUNDS (See Instructions)						
СН	WC CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS o IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)						
CIT 6	CITIZENSHIP OR PLACE OF ORGANIZATION						
Un	ited States		SOLE VOT	ING POV	WER		
NUI	MBER OF	7	0				
	HARES		SHARED V	OTING	POWER		
	EFICIALLY	8					
	NED BY		5,373,368				
	EACH		SOLE DISP	POSITIVI	E POWER		
	PORTING	9	0				
	ERSON		0	NODOGIT			
	WITH	10	SHAKED L)12b0211	TIVE POWER		
		10	5 272 260				
ΔG	5,373,368 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
11	OKLOATE AMOUNT BE	INLITEIALL	1 OWNED	DI LAC.	II KLI OKTINO I LKS	OIV	
	73,368						
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES o							
	CERTAIN SHARES (See Instructions)						
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)							
	29.8% TYPE OF REPORTING PERSON (See Instructions)						
14 IN							

SCHEDULE 13D

CUSIP No. 03969P107		Page 3 of 6 Pages						
NAMES OF REPORT	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS							
Felix J. Baker	CHECK THE APPROPRIATE BOX IF A MEMBER OF A (a) o							
SEC USE ONLY	ons)	(0) 0						
SOURCE OF FUNDS 4	SOURCE OF FUNDS (See Instructions)							
	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS o							
	CITIZENSHIP OR PLACE OF ORGANIZATION							
6 United States		GOLE WOTING POWER						
	7	SOLE VOTING POWER						
NUMBER OF	,	0						
SHARES		SHARED VOTING POWER						
BENEFICIALLY	8							
OWNED BY		5,373,368						
EACH		SOLE DISPOSITIVE POWER						
REPORTING	9							
PERSON		0						
WITH		SHARED DISPOSITIVE POWER						
	10							
		5,373,368						
AGGREGATE AMOU	JNT BENEFICIA	LLY OWNED BY EACH REPORTING PERSON						
11								
5,373,368								
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES								
12 CERTAIN SHARES (
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)								
29.8%	29.8% TYPE OF REPORTING PERSON (See Instructions)							
14 IN	`	•						

This Amendment No. 6 to Schedule 13D is being filed by Julian C. Baker and Felix J. Baker (the "Reporting Persons") to supplement the statements on Schedule 13D previously filed by them, as heretofore amended. Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

Item 5. Interest in Securities of the Issuer.

Set forth below is the aggregate number of shares of Common Stock held, including shares that maybe acquired upon exercise of Warrants, as of the date hereof by each of the following, together with the percentage of outstanding shares of Common Stock that such number represents based upon 17,834,734 shares outstanding according to information received from the Company on December 19, 2008. Such percentage figures are calculated on the basis that the Warrants owned by the Reporting Persons are deemed exercised into shares of Common Stock but other outstanding Warrants are not deemed converted or exercised.

		Percent of
	Number	class
Name	of Shares	Outstanding
Baker Bros.		
Investments, L.P.	88,893	0.5%
Baker Bros.		
Investments II, L.P.	75,388	0.4%
667, L.P.	1,693,159	9.4%
Baker Brothers Life		
Sciences, L.P.	3,341,235	18.5%
14159, L.P.	74,059	0.4%
Baker Tisch		
Investments, L.P.	100,634	0.6%
Total	5,373,368	29.8%

By virtue of their ownership of entities that have the power to control the investment decisions of the limited partnerships listed in the table above, Julian C. Baker and Felix J. Baker may each be deemed to be beneficial owners of shares owned by such entities and may be deemed to have shared power to vote or direct the vote of and shared power to dispose or direct the disposition of such securities.

The following transactions in Common Stock and Warrants were effected by the entities noted below during the sixty days preceding the filing of this statement. All transactions were effected directly with the Company under a Securities Purchase Agreement dated December 19, 2008 in which the entities noted above purchased 794,852 shares of common stock and 198,713 warrants as detailed in the table below. The Warrants are exercisable 180 days after the closing of the transaction at an exercise price of \$11.14 per share and expire in five years from the date of grant.

Edgar Filing: Ardea Biosciences, Inc./DE - Form SC 13D/A

Exhibit 4.

Agreement regarding the joint filing of this statement.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

December 19, 2008

By: /s/ Julian C. Baker Julian C. Baker

By: /s/ Felix J. Baker Felix J. Baker